A symbol of American pharmaceutical innovation for nearly two centuries, Pfizer now faces the challenges of AI adoption and ...

According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai ...

Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its ...

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Savvy investors know that change creates opportunities. And a major change is underway at the nation's central bank. Kevin ...

Vertex Pharmaceuticals announced the FDA has accepted its biologics license application submission for povetacicept, an ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer ...

Durability, not yield, is the deciding factor.